Death and Dysfunction of Transplanted β-Cells: Lessons Learned From Type 2 Diabetes?
- Kathryn J. Potter1,2,
- Clara Y. Westwell-Roper1,2,
- Agnieszka M. Klimek-Abercrombie1,2,
- Garth L. Warnock3 and
- C. Bruce Verchere1,2,3⇑
- 1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- 2Child & Family Research Institute, University of British Columbia, Vancouver, BC, Canada
- 3Department of Surgery, University of British Columbia, Vancouver, BC, Canada
- Corresponding author: C. Bruce Verchere, .
β-Cell replacement by islet transplantation is a potential curative therapy for type 1 diabetes. Despite advancements in islet procurement and immune suppression that have increased islet transplant survival, graft function progressively declines, and many recipients return to insulin dependence within a few years posttransplant. The progressive loss of β-cell function in islet transplants seems unlikely to be explained by allo- and autoimmune-mediated mechanisms alone and in a number of ways resembles β-cell failure in type 2 diabetes. That is, both following transplantation and in type 2 diabetes, islets exhibit decreased first-phase glucose-stimulated insulin secretion, impaired proinsulin processing, inflammation, formation of islet amyloid, signs of oxidative and endoplasmic reticulum stress, and β-cell death. These similarities suggest common mechanisms may underlie loss of insulin production in both type 2 diabetes and islet transplantation and point to the potential for therapeutic approaches used in type 2 diabetes that target the β-cell, such as incretin-based therapies, as adjuncts for immunosuppression in islet transplantation.
- Received April 20, 2012.
- Accepted October 1, 2013.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.